Serum levels of antimicrobial peptides (Cathelicidins and Beta Defensins-1) in patients with periodontitis
Main Article Content
Abstract
Background: periodontitis is a multifactorial oral inflammatory disease characterized by the gradual loss of bone and eventual tooth loss. It starts with microbes and is then influenced by the environment. A diverse family of host defense major compounds known as antimicrobial peptides react quickly to combat microbial invasion and challenge. These little cationic peptides are crucial for the development of innate immunity. The goal of this study was to evaluate the blood levels of healthy individuals and patients with periodontitis for cathelicidins and human beta-defensin-1. In this case-control study, 35 healthy volunteers (matched exactly by age and sex to the patients) and 50 periodontitis patients (aged 20 to 59) participated. In this investigation, periodontal parameters such as plaque index, gingival index bleeding on probing, probing pocket depth, and clinical attachment loss were employed. The levels of cathelicidins and human beta-defensin-1 in patients and controls were estimated using ELISA after blood samples from all individuals were taken. The current findings showed that the mean levels of cathelicidin and human beta defensin-1 were significantly higher (P˂0.01) in the patient group compared to the control group, and that there was no significant correlation with all clinical periodontal parameters. These findings support the notion that antimicrobial peptides play a crucial role in periodontitis' inflammatory process.
Received date: 03-06-2022
Accepted date: 31-07-2022
Published date: 15-03-2024
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licenses and Copyright
The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.
# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner. If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.
# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but that’s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.
# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.
# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.
How to Cite
Publication Dates
References
Petersen PE, Ogawa H: The global burden of periodontal disease: towards integration with chronic disease prevention and control. Periodontol. 2000 2012; 60:15–39. DOI: https://doi.org/10.1111/j.1600-0757.2011.00425.x
Rosier BT, De Jager M, Zaura E, Krom BP: Historical and contemporary hypotheses on the development of oral diseases: are we there yet? Front. Cell. Infect. Microbiol. 2014; 4:92. DOI: https://doi.org/10.3389/fcimb.2014.00092
Slots J. Periodontitis: facts, fallacies and the future. Periodontol 2000 2017;75:7–23. DOI: https://doi.org/10.1111/prd.12221
Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, et al. Periodontitis: consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol 2018;89(Suppl 1):S173–82.
Pasupuleti M, Schmidtchen A, Malmsten M. Antimicrobial peptides: Key components of the innate immune system. Crit. Rev. Biotechnol. 2012, 32, 143–171. DOI: https://doi.org/10.3109/07388551.2011.594423
Gorr S.-U, Abdolhosseini M. Antimicrobial peptides and periodontal disease. J. Clin. Periodontol. 2011, 38, 126–141. DOI: https://doi.org/10.1111/j.1600-051X.2010.01664.x
Khurshid Z, Naseem M, Sheikh Z, Najeeb S, Shahab S, Zafar MS. Oral antimicrobial peptides: Types and role in the oral cavity. Saudi Pharm. J. 2016, 24, 515–524. DOI: https://doi.org/10.1016/j.jsps.2015.02.015
Ouhara K, Komatsuzawa H, Yamada S, Shiba H, Fujiwara T, Ohara M, et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cells. J. Antimicrob. Chemother. 2005, 55, 888–896. DOI: https://doi.org/10.1093/jac/dki103
Ji S, Choi Y. Innate immune response to oral bacteria and the immune evasive characteristics of periodontal pathogens. J. Periodontal Implant. Sci. 2013, 43, 3–11. DOI: https://doi.org/10.5051/jpis.2013.43.1.3
Hans M, Hans VM. Epithelial Antimicrobial Peptides: Guardian of the Oral Cavity. Int. J. Pept. 2014, 2014, 1–13. DOI: https://doi.org/10.1155/2014/370297
Kościuczuk EM, Lisowski P, Jarczak J, Strzałkowska N, Jóźwik A, Horbańczuk J, et al. Cathelicidins: family of antimicrobial peptides. A review. Molecular biology reports. 2012 Dec;39(12):10957-70. DOI: https://doi.org/10.1007/s11033-012-1997-x
Tecle T, Tripathi S, Hartshorn KL. Defensins and cathelicidins in lung immunity. Innate immunity. 2010 Jun;16(3):151-9. DOI: https://doi.org/10.1177/1753425910365734
Zanetti M, Gennaro R, Scocchi M, Skerlavaj B. Structure and biology of cathelicidins. The Biology and Pathology of Innate Immunity Mechanisms. 2002:203-18. DOI: https://doi.org/10.1007/0-306-46831-X_17
López-García B, Lee PH, Yamasaki K, Gallo RL. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. Journal of Investigative Dermatology. 2005 Jul 1;125(1):108-15. DOI: https://doi.org/10.1111/j.0022-202X.2005.23713.x
Gorr SU. Antimicrobial peptides of the oral cavity. Periodontol 2000 2009; 51: 152-80. DOI: https://doi.org/10.1111/j.1600-0757.2009.00310.x
Wilson SS, Wiens ME, Smith JG. Antiviral mechanisms of human defensins. J Mol Biol 2013; 425(24): 4965-80. DOI: https://doi.org/10.1016/j.jmb.2013.09.038
Pierson T, Pierson SL, Pinto D, Hoek ML. Cigarette Smoke Extract Induces Differential Expression Levels of Beta-Defensin Peptides in Human Alveolar Epithelial. Tob Induc Dis 2013; 11(1):10. DOI: https://doi.org/10.1186/1617-9625-11-10
Cohen J. Statistical power analysis for the behavioral sciences Lawrence Earlbaum Associates. 20th–.
Chapple IL, Mealey BL, Van Dyke TE, Bartold PM, Dommisch H, Eickholz P, et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. Journal of periodontology. 2018; 89: S74-84. DOI: https://doi.org/10.1002/JPER.17-0719
Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framwork and proposal of a new classification and case definition. Journal of periodontology. 2018; 89: S159-72. DOI: https://doi.org/10.1002/JPER.18-0006
Silness J, Loe H. Periodontal disease in pregnancy II. Correlation between oral hygiene and periodontal condition. Acta Odont Scand. 1964;22:121-135. DOI: https://doi.org/10.3109/00016356408993968
Newbrun E. Indices to measure gingival bleeding. J Periodontol. 1996;67:555-561. Newbrun E. Indices to measure gingival bleeding. J Periodontol. 1996;67:555-561. DOI: https://doi.org/10.1902/jop.1996.67.6.555
Levin L, Zini A, Levine J, Weiss M, Lev R, Taub DC, et al. Demographic profile, Oral Health Impact Profile and Dental Anxiety Scale in patients with chronic periodontitis: a case–control study. International dental journal. 2018 Aug 1;68(4):269-78. DOI: https://doi.org/10.1111/idj.12381
Mahmood HK. Identification of Human Cytomegalovirus (HCMV) and it is Associated with Interleukin‐6 and TumorNecrosis Factor-Alpha Production in Patients with Chronic Periodontitis. A Thesis submitted to the the College of Dentistry / University of Baghdad, for the MSc in Science of Oral Microbiology. 2020.
Albandar JM. Global risk factors and risk indicators for periodontal diseases. Periodontology 2000. 2002 Apr;29(1):177-206. DOI: https://doi.org/10.1034/j.1600-0757.2002.290109.x
Abbas RF. Analysis of Nuclear Factor Kappa and Toll-Like Receptor-4 Genes Polymorphisms and there Associations with Selected Immunological Biomarkers in Iraqi Population with severe Chronic Periodontitis. A Thesis submitted to the College of Dentistry / University of Baghdad, for the Degree of Doctorate of Philosophy in Periodontics.(2019).
Ibrahim SK. Analysis of Salivary MicroRNA-146a and IL-17 A in Chronic Periodontitis and Their Association with Disease Severity. A Thesis submitted to the the College of Dentistry / University of Baghdad, for the MSc in Science of Oral Microbiology.(2020). DOI: https://doi.org/10.36295/ASRO.2021.24420
Murakami S, Mealey BL, Mariotti A, Chapple IL. Dental plaque–induced gingival conditions. Journal of clinical periodontology. 2018 Jun;45:S17-27. DOI: https://doi.org/10.1111/jcpe.12937
Glimvall P, Wickström C, Jansson H. Elevated levels of salivary lactoferrin, a marker for chronic periodontitis?. Journal of periodontal research. 2012 Oct;47(5):655-60. DOI: https://doi.org/10.1111/j.1600-0765.2012.01479.x
Claffey N, Egelberg J. Clinical indicators of probing attachment loss following initial periodontal treatment in advanced periodontitis patients. Journal of clinical periodontology. 1995 Sep;22(9):690-6. DOI: https://doi.org/10.1111/j.1600-051X.1995.tb00828.x
Checchi L, Montevecchi M, Checchi V, Zappulla F. The relationship between bleeding on probing and subgingival deposits. An endoscopical evaluation. The Open Dentistry Journal. 2009;3:154. DOI: https://doi.org/10.2174/1874210600903010154
Sakalauskiene J, Giedrimiene D, Kubilius R, Gleiznys A, Vitkauskiene A, Ivanauskiene E, et al. Cytokine production by leukocytes in patients with periodontitis. Central European Journal of Medicine. 2014 Dec;9(6):821-9. DOI: https://doi.org/10.2478/s11536-014-0699-2
Tarannum F, Faizuddin M. Association between lipoxin A4 and interleukin‐12 in gingival crevicular fluid: a preliminary investigation. Journal of Periodontal Research. 2017 Apr;52(2):210-7. DOI: https://doi.org/10.1111/jre.12383
Newman MG, Takei HH, Carranza FA. Carranza's clinical periodontology, St. Louis, Missouri, Elsevier Inc.(2018).
Cheah CW, Al-Maleki AR, Vadivelu J, Danaee M, Sockalingam S, Baharuddin NA, et al. Salivary and serum cathelicidin LL-37 levels in subjects with rheumatoid arthritis and chronic periodontitis. Int J Rheum Dis. 2020 Oct;23(10):1344-1352. DOI: https://doi.org/10.1111/1756-185X.13919
Puklo M, Guentsch A, Hiemstra PS, Eick S, Potempa J. Analysis of neutrophil‐derived antimicrobial peptides in gingival crevicular fluid suggests importance of cathelicidin LL‐37 in the innate immune response against periodontogenic bacteria. Oral microbiology and immunology. 2008 Aug;23(4):328-35. DOI: https://doi.org/10.1111/j.1399-302X.2008.00433.x
Eick S, Puklo M, Adamowicz K, Kantyka T, Hiemstra P, Stennicke H, et al. Lack of cathelicidin processing in Papillon-Lefevre syndrome patients reveals essential role of LL-37 in periodontal homeostasis. Orphanet journal of rare diseases. 2014 Dec;9(1):1 DOI: https://doi.org/10.1186/s13023-014-0148-y
Turkoglu O, Emingil G, Eren G, Atmaca H, Kutukculer N, Atilla G. Gingival crevicular fluid and serum hCAP18/LL-37 levels in generalized aggressive periodontitis. Clinical oral investigations. 2017 Apr;21(3):763-9. DOI: https://doi.org/10.1007/s00784-016-1834-z
Bals R, Wilson J. Cathelicidins-a family of multifunctional antimicrobial peptides. Cellular and Molecular Life Sciences CMLS. 2003 Apr;60(4):711-20. DOI: https://doi.org/10.1007/s00018-003-2186-9
Sørensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood, The Journal of the American Society of Hematology. 2001 Jun 15;97(12):3951-9. DOI: https://doi.org/10.1182/blood.V97.12.3951
Bedran TB, Mayer MP, Spolidorio DP, Grenier D. Synergistic anti-inflammatory activity of the antimicrobial peptides human beta-defensin-3 (hBD-3) and cathelicidin (LL-37) in a three-dimensional co-culture model of gingival epithelial cells and fibroblasts. PLoS One. 2014 Sep 4;9(9):e106766. DOI: https://doi.org/10.1371/journal.pone.0106766
Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular immunology. 2012 Nov 1;280(1):22-35. DOI: https://doi.org/10.1016/j.cellimm.2012.11.009
Al-Ali GM, Jafar ZJ, AL-Ghurabi BH. The relation of salivary cathelicidin and beta-defensin with dental caries of schoolchildren. J Res Med Dent Sci. 2021 Apr;9(4):30-5.
Al-Ghurabi BH, Adham ZS, Abbas AA. Level of β-defensin among Iraqi patients with COVID-19 in relation to oral health status. Journal of Emergency Medicine, Trauma and Acute Care. 2022 May 31;2022(3-The International and Scientific Conference of Alnahrain College of Medicine and Colleges of Medicine in Iraq confronting COVID-19 Pandemic (ISMC-2022)):2. DOI: https://doi.org/10.5339/jemtac.2022.ismc.2
Hosokawa I, Hosokawa Y, Komatsuzawa H, Goncalves RB, Karimbux N, Napimoga MH, et al. Innate immune peptide LL-37 displays distinct expression pattern from beta-defensins in inflamed gingival tissue. Clinical & Experimental Immunology. 2006 Nov;146(2):218-25. DOI: https://doi.org/10.1111/j.1365-2249.2006.03200.x
Türkoğlu O, Emingil G, Kütükçüler N, Atilla G. Gingival crevicular fluid levels of cathelicidin LL‐37 and interleukin‐18 in patients with chronic periodontitis. Journal of periodontology. 2009 Jun;80(6):969-76. DOI: https://doi.org/10.1902/jop.2009.080532
Yilmaz D, Topcu AO, Akcay EU, Altındis M, Gursoy UK. Salivary human beta-defensins and cathelicidin levels in relation to periodontitis and type 2 diabetes mellitus. Acta Odontologica Scandinavica. 2020 Jul 3;78(5):327-31. DOI: https://doi.org/10.1080/00016357.2020.1715471
Lu Q, Jin L, Darveau RP, Samaranayake LP. Expression of human beta-defensins-1 and -2 peptides in unresolved chronic periodontitis. J Periodont Res 2004;39: 221–227. DOI: https://doi.org/10.1111/j.1600-0765.2004.00727.x
Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3:710–20. Doi.org/10.1038/nri1180 DOI: https://doi.org/10.1038/nri1180
Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, et al. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun. 1999;67(6):2740–2745. DOI: https://doi.org/10.1128/IAI.67.6.2740-2745.1999
Costa LC, Soldati KR, Fonseca DC, Costa JE, Abreu MH, Costa FO, et al. Gingival crevicular fluid levels of human beta‐defensin 1 in individuals with and without chronic periodontitis. Journal of Periodontal Research. 2018 Oct;53(5):736-42. DOI: https://doi.org/10.1111/jre.12558
Dommisch H, Acil Y, Dunsche A, Winter J, Jepsen S. Differential gene expression of human β‐defensins (hBD‐1,‐2,‐3) in inflammatory gingival diseases. Oral microbiology and immunology. 2005 Jun;20(3):186-90. DOI: https://doi.org/10.1111/j.1399-302X.2005.00211.x
Vardar‐Sengul S, Demirci T, Sen BH, Erkizan V, Kurulgan E, Baylas H. Human β defensin‐1 and‐2 expression in the gingiva of patients with specific periodontal diseases. Journal of periodontal research. 2007 Oct;42(5):429-37. DOI: https://doi.org/10.1111/j.1600-0765.2006.00964.x